IMCR
Immunocore Holdings plc
stockNASDAQADR
immunocore is a privately owned biotechnology company developing innovative biological therapeutics for the treatment of a range of serious diseases. its world-leading t cell receptor technology exploits the power of the body's own immune system to find and kill diseased cells. immunocore has established a robust technology platform which combines monoclonal t cell receptor (mtcr) targeting technology with an effector technology, anti-cd3 scfv, that catalyses the killing of the targeted diseased cells by the host's own non-specific cytotoxic t cells. immunocore is developing a portfolio of products from the platform, called immtacs, for the treatment of cancer, chronic infectious disease and diabetes.
| Period | Price | Date | Change | Beta |
|---|---|---|---|---|
| 1W | 30.64 | 2026-09-28 | -2.86% | -2.080 |
| 1M | 36.13 | 2026-09-04 | -17.62% | 0.744 |
| 3M | 31.94 | 2026-07-06 | -6.81% | 0.063 |
| 6M | 31.94 | 2026-04-06 | -6.81% | 0.381 |
| 1Y | 34.21 | 2025-10-03 | -12.99% | 0.636 |
| 2Y | 31.11 | 2024-10-04 | -4.32% | — |
| 5Y | 38.08 | 2021-10-04 | -21.84% | 0.767 |
Immunocore Holdings plc (NASDAQ:IMCR) stock price today is $29.77, and today's volume is 657,606. IMCR is down 2.538% today. The 30 day average volume is 386,714. IMCR market cap is $1.53B with 51.50M shares outstanding.